CAPTRUST FINANCIAL ADVISORS

Position in OCGN — Ocugen, Inc.

CIK 1512024 RALEIGH, NC

Position in OCGN

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$126,700

+$45,700 QoQ

Shares Held

70,000

+16.7% QoQ

Ownership

0.021%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2021

14 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

CAPTRUST FINANCIAL ADVISORS holds $129,108,622 across 94 Biotechnology names. OCGN ranks #62 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	38,502	$29,748,185
2	VRTX	Vertex Pharmaceuticals Inc / Ma	32,092	$14,330,361
3	EXEL	Exelixis, Inc.	312,296	$13,394,375
4	HALO	Halozyme Therapeutics, Inc.	121,088	$7,825,917
5	CELC	Celcuity Inc.	61,068	$6,970,301
6	RPRX	Royalty Pharma plc	143,760	$6,896,167
7	LGND	Ligand Pharmaceuticals Inc	29,900	$5,969,535
8	INCY	Incyte Corp	53,555	$5,040,596

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$126,700	70,000	+16.7%	Shares	Sole	2026-05-15
2025-12-31	$81,000	60,000	-0.0%	Shares	Sole	2026-02-17
2025-09-30	$97,803	60,002	-1.1%	Shares	Sole	2025-11-19
2025-06-30	$58,840	60,660	+0.5%	Shares	Sole	2025-08-15
2025-03-31	$42,630	60,383	+0.6%	Shares	Sole	2025-05-15
2024-12-31	$48,300	60,000	-0.3%	Shares	Sole	2025-02-14
2024-09-30	$59,672	60,154	+0.3%	Shares	Sole	2024-11-14
2024-06-30	$93,000	60,000	0.0%	Shares	Sole	2024-08-15
2024-03-31	$98,400	60,000	0.0%	Shares	Sole	2024-05-15
2023-12-31	$34,500	60,000	-0.1%	Shares	Sole	2024-02-14
2023-09-30	$24,036	60,090	+200.5%	Shares	Sole	2023-11-15
2023-06-30	$10,860	20,000	+1999900.0%	Shares	Sole	2023-08-15
2021-12-31	$4	1	-99.9%	Shares	Sole	2022-02-14
2021-03-31	$10,185	1,500	—	Shares	Sole	2021-05-17
No filing history on record for this holder in this stock.